title: Optimal design and endpoint of clinical trials using immune checkpoint blocking agents.
authors.affiliation: a Department of Internal Medicine , Seoul National University Hospital , Seoul , Republic of Korea.
authors.forename: Bhumsuk
authors.initials: B
authors.lastname: Keam
authors.affiliation: b Merck Sharp & Dohme , Seoul , Republic of Korea.
authors.forename: Hun
authors.initials: H
authors.lastname: Jung
authors.affiliation: c National Cancer Center , Goyang , Republic of Korea.
authors.forename: Byung Ho
authors.initials: BH
authors.lastname: Nam
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D023381:Endpoint Determination; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D012107:Research Design
chemical_list: D000074322:Antineoplastic Agents, Immunological
keywords: Immune checkpoint blocking agents; PD-1; PD-L1; clinical trial design; endpoint